People living with type 2 diabetes who also develop periodontitis show markedly higher blood levels of three inflammatory and vascular biomarkers—soluble TNF-like weak inducer of apoptosis (sTWEAK), plasminogen activator inhibitor-1 (PAI-1), and galectin-3 (Gal-3)—according to a retrospective study published in BMC Medical Genomics.
The research team analyzed data from 305 patients with type 2 diabetes mellitus, dividing them into a periodontitis group and a non-periodontitis group. For each participant, the investigators collected clinical data, standard periodontal clinical parameters, and direct measurements of gingival microcirculation, including gingival blood flow (GBF) and blood current velocity (BCV). Serum concentrations of the three biomarkers were quantified using enzyme-linked immunosorbent assays (ELISA).
The results were consistent across all three molecules. Patients in the periodontitis group had significantly elevated serum levels of sTWEAK, PAI-1, and Gal-3 compared with diabetic patients whose periodontal tissues were unaffected.
Correlation analyses using Pearson’s and Spearman’s methods revealed that all three biomarkers were positively associated with periodontal clinical parameters, meaning higher blood levels tracked with worse periodontal status. In contrast, the biomarkers were negatively correlated with gingival blood flow and blood current velocity. In other words, patients with the highest biomarker concentrations tended to have the weakest microcirculatory perfusion in their gum tissue, a pattern consistent with the idea that inflammatory signaling and impaired microvascular function occur together in diabetic periodontitis.
To determine whether these associations held up under statistical adjustment, the researchers performed multivariate logistic regression. Elevated levels of sTWEAK, PAI-1, and Gal-3 each emerged as independent risk factors for periodontitis in patients with type 2 diabetes, while increased gingival blood flow and blood current velocity acted as protective factors. This bidirectional pattern—higher inflammatory biomarkers and lower microcirculatory perfusion both pointing toward periodontitis—strengthens the case that gingival microcirculatory dysfunction is intertwined with the systemic inflammatory profile in these patients.
The study also tested whether the biomarkers could discriminate between diabetic patients with and without periodontitis using receiver operating characteristic (ROC) curve analysis. Individually, the areas under the curve (AUCs) were 0.851 for sTWEAK, 0.841 for PAI-1, and 0.854 for Gal-3, all indicating reasonably strong discriminatory ability. When the three biomarkers were combined, the AUC rose significantly to 0.909, showing that the panel outperformed any single marker. A combined biomarker approach may therefore offer a more reliable laboratory signature of periodontitis in the diabetic population than any one protein alone.
The authors conclude that patients with type 2 diabetes and periodontitis exhibited elevated serum sTWEAK, PAI-1, and Gal-3, and that these elevations were associated with periodontal destruction and impaired gingival microcirculation. Because the measurements capture both tissue-level damage (periodontal parameters) and vessel-level function (blood flow and velocity), the findings sketch a coherent picture in which systemic inflammation, periodontal breakdown, and microvascular impairment cluster together in this patient group.
Several caveats deserve emphasis. The study was retrospective, meaning it observed existing differences between groups rather than following patients forward in time, so it cannot establish that the biomarkers cause periodontitis or microcirculatory dysfunction—only that the associations are statistically robust in this cohort. The article was also released as an accepted manuscript shared early for faster access, a citable version that will be replaced by the final Version of Record after further edits. As with any cross-group comparison in a single patient population, the discriminatory values reported here would need validation in independent cohorts before any clinical use.
What this study contributes is a combined view: three serum biomarkers, measured in the same patients alongside direct gingival microcirculatory measurements, showing convergent associations with both periodontal severity and reduced gum blood flow. If confirmed prospectively, such a biomarker panel could eventually help identify which patients with type 2 diabetes carry the greatest periodontal risk, though the current findings remain observational and do not support clinical recommendations on their own.
Subject of Research: Serum biomarkers sTWEAK, PAI-1, and galectin-3 and their association with periodontitis and gingival microcirculatory dysfunction in type 2 diabetes
Article Title: Serum levels of sTWEAK, PAI-1, and galectin-3 in patients with type 2 diabetes mellitus combined with periodontitis: association with gingival microcirculatory dysfunction
Article References: Wu, T., Zhang, R., Gao, Z., Zhao, X., Hu, T., Zhenzhen, W., & Ma, Q. (2026). Serum levels of sTWEAK, PAI-1, and galectin-3 in patients with type 2 diabetes mellitus combined with periodontitis: association with gingival microcirculatory dysfunction. BMC Medical Genomics. https://doi.org/10.1186/s12920-026-02475-7
Image Credits: AI Generated
DOI: 10.1186/s12920-026-02475-7
Keywords: type 2 diabetes, periodontitis, sTWEAK, PAI-1, galectin-3, gingival microcirculation, biomarkers, ELISA, ROC analysis, retrospective study, BMC Medical Genomics, Serum
News Source: Gregory Coleman. (October 28, 2026). Blood biomarkers track gum disease and gingival microcirculation in type 2 diabetes. Scienmag.
